Bioactivities of peptide fractions derived from proteolytic enzyme-injected Hanwoo longissimus muscle in a model system

Figures & data

Table 1. Yield, angiotensin I-converting enzyme inhibitory activity (IC₅₀), and vitamin C equivalents antioxidant capacity (VCEAC) of released crude peptide fractions derived from Hanwoo injected with enzymes.

Treatment^a)	Yield (%)	IC50^b (µg/mL)	VCEAC (mg/100 mL)
Control	1.85 ± 0.04^f,c	1,206 ± 126^d	6.5 ± 0.1^e
PFE1	2.1 ± 0.1^e	21 ± 6^e	5.83 ± 0.08^f
PFE2	3.98 ± 0.03^d	2.33 ± 0.04^f	7.6 ± 0.1^d
PFE3	3.94 ± 0.06^d	31 ± 7^e	5.3 ± 0.2^f

^aTreatments: Control, crude peptide fractions derived from Hanwoo beef injected with no enzymes; PFE1, crude peptide fractions derived from Hanwoo beef injected with protease type XIII; PFE2, crude peptide fractions derived from Hanwoo beef injected with thermolysin; PFE3, crude peptide fractions derived from Hanwoo beef injected with combination of protease type XIII and thermolysin.

^bIC₅₀ represents the inhibitory concentration 50%.

^cMean ± SE.

^d-fMeans with different letters in the same column differ significantly (P < 0.05).

Table 2. Probability values (P-values) of all main effects and interactions on normal cell (3T3-L1 mouse preadipocyte) and human cancer cells (HT29 colon adenocarcinoma cells, HeLa cervix epithelioid carcinoma cells, and HepG2 hepatocarcinoma cells).

Source of variation	3T3-L1	HT29	HeLa	HepG2
Treatments^a	0.755	0.016*	0.513	0.113
Concentration of treatments	0.922	0.303	0.003**	0.311
Treatments × concentration of treatments	0.997	0.859	0.968	0.898

^aTreatments: type of crude peptide fractions derived from injected Hanwoo with two different enzymes independently or as a combination of two different enzymes.

*P < 0.05, **P < 0.01.

Figure 1. Effect of the type of crude peptide fractions derived from injected Hanwoo with enzymes or its concentration on cell viability of HT29 human colon adenocarcinoma cells (A; SEM = 8.89) or HeLa human cervix epithelioid carcinoma cells (B; SEM = 5.63), respectively. Error bars indicate standard error of means. Types of crude peptide fractions: N, cells treated without peptide fractions; luteolin, cells treated with luteolin, CC, cells treated with peptide fraction derived from injected Hanwoo with no enzyme; CPFE1, cells treated with peptide fraction derived from injected Hanwoo with protease type XIII; CPFE2, cells treated with peptide fraction derived from injected Hanwoo with thermolysin; CPFE3, cells treated with peptide fraction derived from injected Hanwoo with combination of protease type XIII and thermolysin. ^A-B Means with different letters on the bar are significantly different (P < 0.05).